Suresch Vijay

Dr Vijay is R&D Lead for the IMDs team and Principal Investigator in the U.K for:

• Hunter Intrathecal Therapy (HIT -045/046 -Shire) Phase I-II clinical trials ( 2012 – Present )
• KOGNITO – Phase IV – 7 Year Neurocognitive outcome study in children with PKU treated with Kuvan (Sapropterin Hydrochloride) – (Merck Serono)
• An Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously ( Synageva/Alexion) NGLU-CL01T
• Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in MPS IIIB (NGLU-CL02) (Synageva/Alexion)
• A Phase 2b/3 prospective, Randomized, Double-Blind, Sham-Controlled Trial of VTS270 (2-Hydroxypropyl-î2-cyclodextrin) in Subjects with Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) disease.
• Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency (LAL-CL08) ( Synageva/ Alexion)
• Clinical evaluation of the performance of a exhaled air ammonia measurement device for its ability to measure levels of systemic ammonia (Innovate UK)
• Next Generation Sequencing in Newborn Screening Project Sponsor – Sheffield Children’s NHS Foundation Trust

Dr Vijay is member of several scientific Societies and Organizations including:
– Member of the British Inherited Metabolic Disease Group (BIMDG)
– Member of the Royal College of Paediatrics and Child Health (RCPCH)
– Member of the Society for Study of Inborn Errors of Metabolism (SSIEM)